Amicus Therapeutics Inc. Stock
Price
Target price
€5.75
€5.75
-
-
-
€16.22
11.08.25 / Frankfurt
WKN: A0MSMZ / Symbol: FOLD / Name: Amicus / Stock / Pharmaceuticals / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Amicus Therapeutics Inc. Stock
With 11 Buy predictions and not the single Sell prediction the community is currently very high on Amicus Therapeutics Inc..
Based on the current price of 5.75 € the target price of 16 € shows a potential of 178.26% for Amicus Therapeutics Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Amicus Therapeutics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Amicus Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Amicus Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amicus Therapeutics Inc. | - | 5.505% | 8.491% | -44.175% | -37.158% | -52.954% | -55.078% |
| Repligen Corp. | 1.000% | -6.180% | -12.124% | -36.932% | -31.118% | -59.657% | -20.331% |
| Opko Health Inc. | 2.830% | -2.290% | -7.330% | -22.117% | -26.278% | -59.882% | -76.581% |
| Hutchison China Meditech Ltd | 3.310% | -14.184% | -5.469% | -29.651% | -6.202% | -6.923% | -54.167% |
Comments
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $17.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $21.00 price target on the stock.
Show more
Ratings data for FOLD provided by MarketBeat
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for FOLD provided by MarketBeat
News
Amicus (FOLD) Q2 Revenue Jumps 22%
Amicus Therapeutics (NASDAQ:FOLD), a specialist in rare disease medicines, delivered quarterly results on July 31, 2025 that notably surpassed expectations on both GAAP revenue and non-GAAP
